Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants With Myelofibrosis and Anemia

Next Previous
X
Search
Trial Profile

A Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants With Myelofibrosis and Anemia

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DISC 0974 (Primary)
  • Indications Anaemia; Myelofibrosis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Disc Medicine

    • Most Recent Events

    • 08 Aug 2024 According to a Disc Medicine Media Release, company Plan to provide an update on regulatory interactions for DISC-0974 in anemia of MF in the second half of 2024.
    • 14 Jun 2024 According to a Disc Medicine Media Release, management will host a call to review the presented data on Friday, June 14th at 8:00 am ET.
    • 14 Jun 2024 According to a Disc Medicine Media Release, data from this study presented at the European Hematology Association (EHA) 2024 Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top